NASDAQ:UTHR

United Therapeutics Stock Competitors

$200.08
-5.06 (-2.47 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$199.06
$204.98
50-Day Range
$179.86
$214.88
52-Week Range
$98.37
$216.90
Volume591,346 shs
Average Volume354,381 shs
Market Capitalization$8.99 billion
P/E Ratio19.44
Dividend YieldN/A
Beta0.49

United Therapeutics (NASDAQ:UTHR) Vs. AMGN, GILD, REGN, VRTX, BIIB, and SGEN

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Seagen (SGEN). These companies are all part of the "biotechnology" industry.

Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares Amgen and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen22.55%99.85%15.16%
United Therapeutics29.60%13.69%10.18%

Volatility and Risk

Amgen has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Institutional and Insider Ownership

74.7% of Amgen shares are held by institutional investors. Comparatively, 95.0% of United Therapeutics shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 12.1% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Amgen and United Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen291102.41
United Therapeutics00803.00

Amgen currently has a consensus price target of $249.4211, suggesting a potential upside of 13.69%. United Therapeutics has a consensus price target of $224.3750, suggesting a potential upside of 12.14%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than United Therapeutics.

Valuation & Earnings

This table compares Amgen and United Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$25.42 billion4.90$7.26 billion$16.6013.22
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34

Amgen has higher revenue and earnings than United Therapeutics. Amgen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats United Therapeutics on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

78.0% of Gilead Sciences shares are held by institutional investors. Comparatively, 95.0% of United Therapeutics shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 12.1% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Gilead Sciences and United Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$24.69 billion3.64$123 million$7.0910.10
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34

United Therapeutics has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Gilead Sciences and United Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences071002.59
United Therapeutics00803.00

Gilead Sciences currently has a consensus price target of $109.8750, suggesting a potential upside of 53.44%. United Therapeutics has a consensus price target of $224.3750, suggesting a potential upside of 12.14%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than United Therapeutics.

Profitability

This table compares Gilead Sciences and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences19.38%55.94%15.71%
United Therapeutics29.60%13.69%10.18%

Volatility and Risk

Gilead Sciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Summary

United Therapeutics beats Gilead Sciences on 9 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

95.0% of United Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 12.1% of United Therapeutics shares are owned by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares United Therapeutics and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34
Regeneron Pharmaceuticals$8.50 billion8.21$3.51 billion$28.6622.75

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for United Therapeutics and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00803.00
Regeneron Pharmaceuticals041302.76

United Therapeutics currently has a consensus price target of $224.3750, indicating a potential upside of 12.14%. Regeneron Pharmaceuticals has a consensus price target of $698.3750, indicating a potential upside of 7.13%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares United Therapeutics and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics29.60%13.69%10.18%
Regeneron Pharmaceuticals50.11%50.43%33.56%

Risk & Volatility

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats United Therapeutics on 8 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

95.0% of United Therapeutics shares are owned by institutional investors. Comparatively, 88.6% of Vertex Pharmaceuticals shares are owned by institutional investors. 12.1% of United Therapeutics shares are owned by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares United Therapeutics and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34
Vertex Pharmaceuticals$6.21 billion7.87$2.71 billion$9.0320.85

Vertex Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for United Therapeutics and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00803.00
Vertex Pharmaceuticals251602.61

United Therapeutics currently has a consensus price target of $224.3750, indicating a potential upside of 12.14%. Vertex Pharmaceuticals has a consensus price target of $266.6111, indicating a potential upside of 41.59%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than United Therapeutics.

Profitability

This table compares United Therapeutics and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics29.60%13.69%10.18%
Vertex Pharmaceuticals29.80%29.73%21.96%

Risk & Volatility

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats United Therapeutics on 10 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

95.0% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.2% of Biogen shares are owned by institutional investors. 12.1% of United Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares United Therapeutics and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34
Biogen$13.44 billion3.33$4.00 billion$33.708.91

Biogen has higher revenue and earnings than United Therapeutics. Biogen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for United Therapeutics and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00803.00
Biogen0131602.55

United Therapeutics currently has a consensus price target of $224.3750, indicating a potential upside of 12.14%. Biogen has a consensus price target of $393.3573, indicating a potential upside of 31.04%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than United Therapeutics.

Profitability

This table compares United Therapeutics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics29.60%13.69%10.18%
Biogen16.40%34.74%15.37%

Risk & Volatility

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

Biogen beats United Therapeutics on 8 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Profitability

This table compares United Therapeutics and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
United Therapeutics29.60%13.69%10.18%
Seagen25.06%19.02%16.03%

Analyst Recommendations

This is a summary of recent recommendations for United Therapeutics and Seagen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
United Therapeutics00803.00
Seagen06802.57

United Therapeutics currently has a consensus price target of $224.3750, indicating a potential upside of 12.14%. Seagen has a consensus price target of $184.75, indicating a potential upside of 18.27%. Given Seagen's higher probable upside, analysts clearly believe Seagen is more favorable than United Therapeutics.

Institutional & Insider Ownership

95.0% of United Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Seagen shares are owned by institutional investors. 12.1% of United Therapeutics shares are owned by company insiders. Comparatively, 27.6% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Seagen has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Earnings and Valuation

This table compares United Therapeutics and Seagen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$1.48 billion6.06$514.80 million$11.5417.34
Seagen$2.18 billion13.06$613.67 million$3.3047.34

Seagen has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats United Therapeutics on 9 of the 13 factors compared between the two stocks.


United Therapeutics Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Amgen logo
AMGN
Amgen
2.8$219.38
-0.9%
$249.42
-13.7%
$124.58 billion$25.42 billion22.3224,300Analyst Report
High Trading Volume
Gilead Sciences logo
GILD
Gilead Sciences
3.4$71.61
-0.4%
$75.53
-5.5%
$89.79 billion$24.69 billion17.4713,600Ex-Dividend
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.5$651.88
-0.2%
$698.38
-7.1%
$69.72 billion$8.50 billion11.719,123Analyst Report
Insider Selling
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.8$188.30
-0.6%
$266.61
-41.6%
$48.85 billion$6.21 billion24.843,400
Biogen logo
BIIB
Biogen
2.5$300.19
-0.2%
$393.36
-31.0%
$44.74 billion$13.44 billion24.099,100Analyst Report
News Coverage
Seagen logo
SGEN
Seagen
2.3$156.21
-1.7%
$184.75
-18.3%
$28.42 billion$2.18 billion47.922,092
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
2.1$190.34
-0.1%
$169.33
-11.0%
$22.62 billion$492.85 million-25.081,453
Exact Sciences logo
EXAS
Exact Sciences
2.5$108.15
-5.0%
$151.06
-39.7%
$18.60 billion$1.49 billion-19.815,000Gap Down
Novavax logo
NVAX
Novavax
1.7$237.54
-0.1%
$249.60
-5.1%
$17.69 billion$475.60 million-17.33791Insider Selling
Repligen logo
RGEN
Repligen
2.0$306.90
-2.3%
$259.50
-15.4%
$16.85 billion$366.26 million171.451,128Analyst Report
Analyst Revision
News Coverage
High Trading Volume
Incyte logo
INCY
Incyte
2.7$75.99
-1.3%
$92.29
-21.4%
$16.78 billion$2.67 billion49.991,773High Trading Volume
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$77.76
-1.6%
$103.24
-32.8%
$14.26 billion$1.86 billion18.133,059Analyst Report
High Trading Volume
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.50
-0.8%
$119.31
-23.6%
$9.12 billion$1.05 billion25.94845
Exelixis logo
EXEL
Exelixis
2.7$20.72
-0.9%
$34.50
-66.5%
$6.53 billion$987.54 million71.45773Insider Selling
News Coverage
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
2.5$42.04
-0.0%
$54.14
-28.8%
$5.98 billion$267.59 million26.95288High Trading Volume
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
2.1$37.21
-2.1%
$54.75
-47.1%
$5.25 billion$729 million-9.61757High Trading Volume
Alkermes logo
ALKS
Alkermes
1.9$30.11
-1.1%
$28.25
-6.2%
$4.86 billion$1.04 billion-75.272,245High Trading Volume
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
2.4$61.05
-1.8%
$97.25
-59.3%
$3.73 billion$320,000.00-7.47363
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.3$57.14
-0.6%
$96.50
-68.9%
$3.07 billion$1.56 billion10.312,200
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
2.1$11.00
-0.7%
$18.73
-70.2%
$2.93 billion$260.89 million-11.46483Insider Selling
News Coverage
High Trading Volume
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.0$15.70
-3.1%
$19.45
-23.9%
$2.81 billion$17.81 million-13.08246Analyst Report
Insider Selling
News Coverage
OPKO Health logo
OPK
OPKO Health
2.3$3.94
-3.0%
$6.50
-65.0%
$2.68 billion$1.44 billion35.825,269Insider Buying
Myriad Genetics logo
MYGN
Myriad Genetics
1.5$33.72
-3.3%
$25.33
-24.9%
$2.63 billion$638.60 million-24.612,700Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
2.0$54.39
-2.0%
$57.25
-5.3%
$2.53 billion$7.42 million-32.57124Analyst Report
Analyst Revision
News Coverage
Gap Up
High Trading Volume
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
2.2$144.73
-6.7%
$226.25
-56.3%
$2.41 billion$186.42 million52.252,018Analyst Report
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$12.35
-2.2%
$12.00
-2.8%
$2.01 billion$389.52 million3.96232Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.3$14.89
-3.0%
$21.00
-41.0%
$1.71 billion$46.55 million-57.27245Analyst Report
Analyst Revision
News Coverage
Codexis logo
CDXS
Codexis
1.7$25.58
-3.8%
$30.25
-18.3%
$1.65 billion$69.06 million-69.13181
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.7$9.55
-3.4%
$23.00
-140.8%
$1.39 billion$118.19 million-10.05413News Coverage
Gap Down
Agenus logo
AGEN
Agenus
2.0$5.83
-4.5%
$10.00
-71.5%
$1.36 billion$88.17 million-5.21359Insider Selling
News Coverage
Gap Up
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
2.4$81.74
-1.9%
$172.13
-110.6%
$1.36 billionN/A-5.5942News Coverage
High Trading Volume
ImmunoGen logo
IMGN
ImmunoGen
1.9$5.80
-2.1%
$10.10
-74.1%
$1.17 billion$132.30 million-20.0079High Trading Volume
ChemoCentryx logo
CCXI
ChemoCentryx
1.9$16.57
-3.5%
$37.88
-128.6%
$1.16 billion$64.89 million-9.36133
MannKind logo
MNKD
MannKind
2.1$4.53
-0.7%
$6.20
-36.9%
$1.13 billion$65.14 million-12.94241
Innoviva logo
INVA
Innoviva
1.3$15.65
-2.6%
$10.00
-36.1%
$1.09 billion$336.79 million6.315Gap Down
High Trading Volume
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.7$16.95
-4.1%
$18.00
-6.2%
$943.06 million$248.17 million29.22292Insider Selling
News Coverage
Gap Down
High Trading Volume
Curis logo
CRIS
Curis
2.0$8.48
-1.1%
$21.00
-147.6%
$776.73 million$10.84 million-18.8428
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
2.2$4.86
-5.8%
$12.00
-146.9%
$702.14 million$24 million12.4678Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
2.0$3.90
-1.8%
$11.00
-182.1%
$666.32 million$108.62 million-78.00169News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
2.0$15.29
-2.3%
$40.50
-164.9%
$581.83 million$230,000.00-0.6965Short Interest ↑
News Coverage
High Trading Volume
Clovis Oncology logo
CLVS
Clovis Oncology
1.8$4.84
-4.8%
$6.00
-24.0%
$573.10 million$164.52 million-1.53N/A
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.3$15.93
-3.3%
$33.00
-107.2%
$528.89 million$312.69 million-3.10498Gap Down
Verastem logo
VSTM
Verastem
1.9$2.76
-2.2%
$6.33
-129.5%
$498.89 million$88.52 million-12.0049High Trading Volume
Geron logo
GERN
Geron
1.1$1.41
-0.7%
N/A$452.05 million$250,000.00-4.5554
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
2.3$2.43
-4.1%
$9.00
-270.4%
$398.70 million$109.33 million-1.98176Gap Down
High Trading Volume
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
2.1$1.82
-7.1%
$3.83
-110.6%
$392.32 million$150,000.00-4.33105Gap Down
High Trading Volume
Arctos NorthStar Acquisition logo
ANAC
Arctos NorthStar Acquisition
1.2$9.77
-0.1%
N/A$386.21 millionN/A0.00N/A
Fortress Biotech logo
FBIO
Fortress Biotech
2.1$3.35
-2.1%
$10.60
-216.4%
$338.56 million$45.60 million-8.17111News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.6$5.99
-3.5%
$14.50
-142.1%
$336.29 million$18.84 million-3.27239News Coverage
Gap Up
High Trading Volume
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$3.63
-5.8%
$9.63
-165.2%
$322.05 million$1.72 million-5.9523Gap Down
This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.